Real-world effectiveness of ribociclib 1 aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: The RIBANNA study

Fasching P, Decker T, Guderian G, Heim J, Jackisch C, Lueck HJ, Lueftner D, Marme F, Reimer T, Woeckel A (2018)

Publication Type: Conference contribution

Publication year: 2018

Journal

Annals of Oncology Elsevier

Publisher: OXFORD UNIV PRESS

City/Town: OXFORD

Conference Proceedings Title: ANNALS OF ONCOLOGY

Event location: Munich DE

DOI: 10.1093/annonc/mdy271.275

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

Charité - Universitätsmedizin Berlin DE Germany (DE) Universitätsklinikum Würzburg DE Germany (DE) Universitätsklinikum Heidelberg DE Germany (DE) Novartis Pharma Germany DE Germany (DE) Novartis AG CH Switzerland (CH) Universität Rostock DE Germany (DE) Sana Kliniken AG DE Germany (DE)

How to cite

APA:

Fasching, P., Decker, T., Guderian, G., Heim, J., Jackisch, C., Lueck, H.-J.,... Woeckel, A. (2018). Real-world effectiveness of ribociclib 1 aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: The RIBANNA study. In ANNALS OF ONCOLOGY. Munich, DE: OXFORD: OXFORD UNIV PRESS.

MLA:

Fasching, Peter, et al. "Real-world effectiveness of ribociclib 1 aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: The RIBANNA study." Proceedings of the 43rd ESMO Congress (ESMO), Munich OXFORD: OXFORD UNIV PRESS, 2018.

BibTeX: Download